• Rallybio's merger with Avenzo Therapeutics is expected to close following trading on November 20, 2026, subject to remaining closing conditions.
• Nasdaq cleared the common stock for listing on the Nasdaq Capital Market in connection with the merger.
• Payment of the $13.90-per-share special cash distribution is expected to begin November 30, 2026, unaffected by the planned reverse stock split.
• Contingent value rights are expected to be distributed on November 23, 2026, one business day following the merger's closing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-458624), on November 12, 2026, and is solely responsible for the information contained therein.